We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for Exxon, Duke & Gilead Sciences
Read MoreHide Full Article
Monday, November 7 2016
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM - Free Report) , Gilead (GILD - Free Report) and Duke Energy (DUK - Free Report) .
ExxonMobil shares have lagged the broader energy space this year (the stock is up 7.2% year to date vs. 12% gain for the sector as a whole), reflecting the stock's defensive attributes and relatively less 'oiliness' relative to peers like Chevron (CVX). The stock is nevertheless ahead of the market this year and provides a lower risk way to play the energy space with its integrated model, above peer group average financial returns, a fortress balance sheet and a very safe and attractive dividend currently 3.6%. Exxon's Q3 results were significantly below the year-earlier level, but they were nevertheless better than expected. Comparisons are expected to improve from Q4 onwards. (You can read the full research report on ExxonMobil here>>)
Gilead shares have been laggards this year, losing nearly 28% year-to-date, as the HCV franchise continues to witness slowdown in the U.S. and Europe due to lower sales of Harvoni. The mixed Q3 results and questions about product pipeline didn't help matters either. On top of this are macro headwinds facing all drug makers related to pricing and other regulatory changes that many suspect are steadily shifting in an unfavorable direction. These are no doubt big challenges, but the analyst also points towards the company's robust late-stage pipeline. (You can read the full research report on Gilead here>>)
Duke Energy shares have outperformed the broader market as well as the peer utilities space in the year-to-date period (it is up more than 8%), with the company's better than expected Q3 results adding to the favorable momentum. The analyst likes the company’s strong cash position, as is evident from the solid improvement in its cash equivalents figure. Further, the company’s updated guidance buoys optimism. Being a premier utility service provider, Duke Energy continues to invest in infrastructure and expansion projects. Going ahead, stringent environmental regulations, pending regulatory cases, volatile commodity prices, severe weather patterns and foreign exchange risks may hinder Duke Energy’s performance. (You can read the full research report on Duke Energy here>>)
Today's Private Buys & Sells from Zacks Research While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for Exxon, Duke & Gilead Sciences
Monday, November 7 2016
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM - Free Report) , Gilead (GILD - Free Report) and Duke Energy (DUK - Free Report) .
ExxonMobil shares have lagged the broader energy space this year (the stock is up 7.2% year to date vs. 12% gain for the sector as a whole), reflecting the stock's defensive attributes and relatively less 'oiliness' relative to peers like Chevron (CVX). The stock is nevertheless ahead of the market this year and provides a lower risk way to play the energy space with its integrated model, above peer group average financial returns, a fortress balance sheet and a very safe and attractive dividend currently 3.6%. Exxon's Q3 results were significantly below the year-earlier level, but they were nevertheless better than expected. Comparisons are expected to improve from Q4 onwards. (You can read the full research report on ExxonMobil here>>)
Gilead shares have been laggards this year, losing nearly 28% year-to-date, as the HCV franchise continues to witness slowdown in the U.S. and Europe due to lower sales of Harvoni. The mixed Q3 results and questions about product pipeline didn't help matters either. On top of this are macro headwinds facing all drug makers related to pricing and other regulatory changes that many suspect are steadily shifting in an unfavorable direction. These are no doubt big challenges, but the analyst also points towards the company's robust late-stage pipeline. (You can read the full research report on Gilead here>>)
Duke Energy shares have outperformed the broader market as well as the peer utilities space in the year-to-date period (it is up more than 8%), with the company's better than expected Q3 results adding to the favorable momentum. The analyst likes the company’s strong cash position, as is evident from the solid improvement in its cash equivalents figure. Further, the company’s updated guidance buoys optimism. Being a premier utility service provider, Duke Energy continues to invest in infrastructure and expansion projects. Going ahead, stringent environmental regulations, pending regulatory cases, volatile commodity prices, severe weather patterns and foreign exchange risks may hinder Duke Energy’s performance. (You can read the full research report on Duke Energy here>>)
Other noteworthy reports we are featuring today include Regeneron (REGN - Free Report) , NVIDIA (NVDA - Free Report) and Monster Beverage (MNST - Free Report) .
Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>